F9 Malmö, factor IX and deep vein thrombosis
- PMID: 19286883
- PMCID: PMC2675682
- DOI: 10.3324/haematol.2008.003020
F9 Malmö, factor IX and deep vein thrombosis
Abstract
Background: We recently reported the association between the Malmö sequence variant in F9 (rs6048) and deep vein thrombosis.
Design and methods: We aimed to study whether the association between F9 Malmö and deep vein thrombosis is explained by linkage disequilibrium with nearby single-nucleotide polymorphisms, and whether the association is explained biologically by F9 Malmö affecting factor IX antigen levels or activation of factor IX. We investigated the association of F9 Malmö and 28 nearby single-nucleotide polymorphisms with deep vein thrombosis in men from two case-control studies, LETS (n=380) and MEGA (n=1,469). We assessed the association of F9 Malmö with factor IX antigen level in male control subjects from LETS (n=191) and two subsets of MEGA (n=823 and n=484) and the association with endogenous thrombin potential in LETS control men. We studied the association between F9 Malmö and factor IX activation peptide in 1,199 healthy middle-aged men from the NPHS-II cohort.
Results: In the combined LETS and MEGA studies, the odds ratio (95% confidence interval) for the G allele of F9 Malmö, compared with the A allele, was 0.80 (0.69-0.93). One single-nucleotide polymorphism in F9, rs422187, was strongly linked to F9 Malmö (r(2)=0.94) and was similarly associated with deep vein thrombosis. No other single-nucleotide polymorphism or haplotype tested was more strongly associated. Factor IX antigen level, factor IX activation peptide levels and endogenous thrombin potential did not differ between F9 Malmö genotypes.
Conclusions: The F9 Malmö sequence variant was the most strongly associated with deep vein thrombosis among common single-nucleotide polymorphisms in the region. However, the biological mechanism by which F9 Malmö affects risk remains unknown.
Figures


Comment in
-
Factor IX and deep vein thrombosis.Haematologica. 2009 May;94(5):615-7. doi: 10.3324/haematol.2009.005769. Haematologica. 2009. PMID: 19407317 Free PMC article.
Similar articles
-
Factor IX and deep vein thrombosis.Haematologica. 2009 May;94(5):615-7. doi: 10.3324/haematol.2009.005769. Haematologica. 2009. PMID: 19407317 Free PMC article.
-
Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts.J Thromb Haemost. 2015 Oct;13(10):1815-22. doi: 10.1111/jth.13116. Epub 2015 Sep 7. J Thromb Haemost. 2015. PMID: 26270772
-
Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes.J Thromb Haemost. 2018 Dec;16(12):2432-2441. doi: 10.1111/jth.14279. Epub 2018 Oct 16. J Thromb Haemost. 2018. PMID: 30168256 Free PMC article.
-
Discovering novel risk factors for venous thrombosis: a candidate-gene approach.Thromb Res. 2009;123 Suppl 4(Suppl 4):S25-9. doi: 10.1016/S0049-3848(09)70139-2. Thromb Res. 2009. PMID: 19303500 Free PMC article. Review.
-
Predicting the future: it's not a SNP.J Thromb Haemost. 2008 May;6(5):749-50. doi: 10.1111/j.1538-7836.2008.02922.x. Epub 2008 Jan 31. J Thromb Haemost. 2008. PMID: 18248599 Review. No abstract available.
Cited by
-
Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism.Blood. 2019 Nov 7;134(19):1645-1657. doi: 10.1182/blood.2019000435. Blood. 2019. PMID: 31420334 Free PMC article.
-
Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative.Res Pract Thromb Haemost. 2018 Apr 17;2(2):310-319. doi: 10.1002/rth2.12100. eCollection 2018 Apr. Res Pract Thromb Haemost. 2018. PMID: 30046733 Free PMC article.
-
A study of recurrent life-threatening thrombosis accompanied with the duplication of the factor IX gene.Thromb J. 2024 Jan 2;22(1):1. doi: 10.1186/s12959-023-00570-8. Thromb J. 2024. PMID: 38169400 Free PMC article.
-
Association between venous thromboembolism-associated genetic variants, coagulation factor levels, and thrombin generation potential.EJHaem. 2024 Feb 18;5(1):47-54. doi: 10.1002/jha2.863. eCollection 2024 Feb. EJHaem. 2024. PMID: 38406509 Free PMC article.
-
Evaluating the clinical validity of genes related to hemostasis and thrombosis using the Clinical Genome Resource gene curation framework.J Thromb Haemost. 2024 Mar;22(3):645-665. doi: 10.1016/j.jtha.2023.11.011. Epub 2023 Nov 26. J Thromb Haemost. 2024. PMID: 38016518 Free PMC article.
References
-
- Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerström J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5:692–9. - PubMed
-
- Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756–64. - PubMed
-
- Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457–62. - PubMed
-
- van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678–82. - PubMed
-
- de Visser MCH, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost. 2001;85:1011–7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous